Mass Spectrometry as a Clinical Integrative Tool to Evaluate Hepatocellular Carcinoma: Moving to the Mainstream

References

• Thomson JJ LXXXIII. Rays of positive electricity. London, Edinburgh, Dublin Philos Mag J Sci [Internet]. 1910;20:752–767.
   Google Scholar
• Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene [Internet]. 2010;29:4989–5005.
   PubMed Web of Science ®Google Scholar
• Ayers D, Day PJ. Systems medicine: the application of systems biology approaches for modern medical research and drug development. Mol Biol Int [Internet]. 2015;2015:1–8. Available from: https://www.hindawi.com/archive/2015/698169/
   Google Scholar
• Nicholson JK, Holmes E, Kinross JM, et al. Metabolic phenotyping in clinical and surgical environments. Nature. 2012;491:384–392.
   PubMed Web of Science ®Google Scholar
• Gonzalez SA. Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg Nutr. 2014;3:410–414.
   PubMedGoogle Scholar
• Wong VWS, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28:1660–1665.
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–1014.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Feng Z, Wang Y, et al. α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma. Gastroenterology [Internet]. 2009;137:110–118.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018. DOI:10.1016/j.jhep.2018.03.019
   Web of Science ®Google Scholar
• Kudo M. Alpha-fetoprotein-L3: useful or useless for hepatocellular carcinoma? Liver Cancer [Internet]. 2013;2:151–152.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Prim [Internet]. 2016;2:16018. Available from: http://www.nature.com/articles/nrdp201618.
   PubMed Web of Science ®Google Scholar
• Shirabe K, Toshima T, Kimura K, et al. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int. 2014;34:937–941.
   PubMed Web of Science ®Google Scholar
• Bruix J, Han KH, Gores G, et al. Liver cancer: approaching a personalized care. J Hepatol [Internet]. 2015;62:S144–S156.
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–855.
   PubMed Web of Science ®Google Scholar
• Song P, Feng X, Zhang K, et al. Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China. Biosci Trends. 2013;7:1–6.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Matsuda M, Ohkura Y, et al. The influence of histological differentiation grade on the outcome of liver resection for hepatocellular carcinomas 2 cm or smaller in size. World J Surg [Internet]. 2015;39:1134–1141.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Lei J, Li B, et al. Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single nodule <2 cm): a single-center study. Eur J Gastroenterol Hepatol. 2014;26:339–344.
   PubMed Web of Science ®Google Scholar
• Amin A, Hamza AA, Daoud S, et al. Abstract 5249: crocin prevents early lesions of liver cancer: system biology approach. Cancer Res [Internet]. 2016 [cited 2018 Dec 3];76:5249.
   Web of Science ®Google Scholar
• Wang P, Ouyang L, Zheng L, et al. Identifying hepatocellular carcinoma-related genes and pathways by system biology analysis. Ir J Med Sci. 2015;184:357–364.
   PubMed Web of Science ®Google Scholar
• D’Alessandro LA, Meyer R, Klingmüller U. Hepatocellular carcinoma: a systems biology perspective. Front Physiol. 2013;4 FEB:1–6.
   Web of Science ®Google Scholar
• Pinna F, Sahle S, Beuke K, et al. Abstract 5235: a model for TNFα-mediated NFκB signalling: a systems biology study on hepatocytes and liver cancer cells. Cancer Res [Internet]. 2013 [cited 2018 Dec 3];73:5235.
   Google Scholar
• Balog J, Sasi-Szabo L, Kinross J, et al. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med [Internet]. 2013;5:194ra93.
   PubMed Web of Science ®Google Scholar
• Alexander J, Gildea L, Balog J, et al. A novel methodology for in vivo endoscopic phenotyping of colorectal cancer based on real-time analysis of the mucosal lipidome: a prospective observational study of the iKnife. Surg Endosc Other Interv Tech. 2017;31:1361–1370.
   PubMed Web of Science ®Google Scholar
• Stopka SA, Rong C, Korte AR, et al. Molecular imaging of biological samples on nanophotonic laser desorption ionization platforms. Angew Chemie Int Ed. 2016;55:4482–4486.
   PubMed Web of Science ®Google Scholar
• Fincher JA, Dyer JE, Korte AR, et al. Matrix-free mass spectrometry imaging of mouse brain tissue sections on silicon nanopost arrays. J Comp Neurol [ Internet]. 2018. DOI:10.1002/cne.24566.
   PubMed Web of Science ®Google Scholar
• Zhang J, Rector J, Lin JQ, et al. Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system. Sci Transl Med [Internet]. 2017;9:eaan3968.
   PubMed Web of Science ®Google Scholar
• Nie W, Yan L, Lee YH, et al. Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma. Mass Spectrom Rev [Internet]. 2016;35:331–349. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24890331.
   PubMed Web of Science ®Google Scholar
• Kimhofer T, Fye H, Taylor-Robinson S, et al. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer [Internet]. 2015;112:1141–1156.
   PubMed Web of Science ®Google Scholar
• Lu Y, Huang C, Gao L, et al. Identification of serum biomarkers associated with hepatitis B virus-related hepatocellular carcinoma and liver cirrhosis using mass-spectrometry-based metabolomics. Metabolomics [Internet]. 2015;11:1526–1538.
   Web of Science ®Google Scholar
• Pijls KE, Smolinska A, Jonkers DMAE, et al. A profile of volatile organic compounds in exhaled air as a potential non-invasive biomarker for liver cirrhosis. Sci Rep [Internet]. 2016;6:1–8.
   PubMed Web of Science ®Google Scholar
• Gong Z-G, Zhao W, Zhang J, et al. Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis. Oncotarget [Internet]. 2017;8:63890–63900. Available from: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article⊕download&path%5B%5D=19173&path%5B%5D=61394%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=618472762.
   PubMedGoogle Scholar
• Becker S, Kinny-Köster B, Bartels M, et al. Low sphingosine-1-phosphate plasma levels are predictive for increased mortality in patients with liver cirrhosis. Cowart A, editor. PLoS One [Internet]. 2017;12:e0174424.
   PubMed Web of Science ®Google Scholar
• Gao R, Cheng J, Fan C, et al. Serum metabolomics to identify the liver disease-specific biomarkers for the progression of hepatitis to hepatocellular carcinoma. Sci Rep [Internet]. 2015;5:1–10.
   Web of Science ®Google Scholar
• Wu C, Liu L, Zhao P, et al. Potential serum markers for monitoring the progression of hepatitis B virus-associated chronic hepatic lesions to liver cirrhosis. Gut Liver. 2015;9:665–671.
   PubMed Web of Science ®Google Scholar
• Park H, Kim SU, Park JY, et al. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. Liver Int [Internet]. 2014;34:313–321.
   PubMed Web of Science ®Google Scholar
• Lee SC, Tan HT, Chung MCM. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol. 2014;20:3112–3124.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu GY, Wu YJ, et al. The serum metabolic profiles of different Barcelona stages hepatocellular carcinoma associated with hepatitis B virus. Oncol Lett. 2018;15:956–962.
   PubMed Web of Science ®Google Scholar
• Lu NT, Liu NM, Vu JQ, et al. Phospho-network analysis identifies and quantifies hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC) proteins regulating viral-mediated tumor growth. Cancer Genomics Proteomics. 2016;13:339–358.
   PubMed Web of Science ®Google Scholar
• Safaei A, Oskouie AA, Mohebbi SR, et al. Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterol Hepatol Bed Bench. 2016;9:158–173.
   PubMedGoogle Scholar
• Gorden DL, Myers DS, Ivanova PT, et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res [Internet]. 2015;56:722–736.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Wong VW-S, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Prim [Internet]. 2015;44:15080. Available from: http://www.nature.com/articles/nrdp201580.
   Google Scholar
• Tiwari-Heckler S, Gan-Schreier H, Stremmel W, et al. Circulating phospholipid patterns in NAFLD patients associated with a combination of metabolic risk factors. Nutrients. 2018;10(5):649.
   PubMed Web of Science ®Google Scholar
• Chiappini F, Coilly A, Kadar H, et al. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients. Sci Rep [Internet]. 2017;7:46658.
   PubMed Web of Science ®Google Scholar
• Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology. 2014;59:2034–2042.
   PubMed Web of Science ®Google Scholar
• Yang W, Lu Y, Xu Y, et al. Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem. 2012;287:40140–40149.
   PubMed Web of Science ®Google Scholar
• Wang S, Xu M, Li X, et al. Exosomes released by hepatocarcinoma cells endow adipocytes with tumor-promoting properties. J Hematol Oncol. 2018;11:1–14.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Q, Lou Y, et al. Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. Hepatology [Internet]. 2018;67:1872–1889.
   PubMed Web of Science ®Google Scholar
• Ifa DR, Eberlin LS. Ambient ionization mass spectrometry for cancer diagnosis and surgical margin evaluation. Clin Chem. 2016;62:111–123.
   PubMed Web of Science ®Google Scholar
• Eberlin LS, Norton I, Dill AL, et al. Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res [Internet]. 2012;72:645–654. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22139378.
   PubMed Web of Science ®Google Scholar
• St John ER, Balog J, McKenzie JS, et al. Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgery. Breast Cancer Res [Internet]. 2017;19:59.
   PubMed Web of Science ®Google Scholar
• Miyoshi F, Honne K, Minota S, et al. A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab. Mod Rheumatol. 2016;26:813–816.
   PubMed Web of Science ®Google Scholar
• Chocholova E, Bertok T, Jane E, et al. Glycomics meets artificial intelligence – potential of glycan analysis for identification of seropositive and seronegative rheumatoid arthritis patients revealed. Clin Chim Acta. 2018;481:49–55.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Washburn WK, Halff G, et al. Abstract 1567: a mass spectrometry based serum test for the detection of hepatocellular carcinoma (HCC) in high risk patients. Cancer Res [Internet]. 2015 [cited 2018 Dec 3];75:1567.
   PubMed Web of Science ®Google Scholar
• Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871.
   PubMed Web of Science ®Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology [Internet]. 2001;33:464–470. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11172350.
   PubMed Web of Science ®Google Scholar
• Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology [Internet]. 2007;45:797–805.
   PubMed Web of Science ®Google Scholar